Feb 2019 Science.org: Resumed Gain of Function experiments funded by NIAID (Fauci's institute)
Science.org Insider: a U.S. gov review panel quietly approved experiments proposed by two labs that were previously considered so dangerous that federal officials had imposed a top-down moratorium.
Science Insider has learned that last year [2018], a U.S. government review panel quietly approved experiments proposed by two labs that were previously considered so dangerous that federal officials had imposed an unusual top-down moratorium on such research.
One of the projects has already received funding from the National Institutes of Health's (NIH's) National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, and will start in a few weeks [March 2019]; the other is awaiting funding.
”After a deliberative process that cost $1 million for [a consultant’s] external study and consumed countless weeks and months of time for many scientists, we are now being asked to trust a completely opaque process where the outcome is to permit the continuation of dangerous experiments.”
— Marc Lipsitch, Harvard University epidemiologist
Why the Composite Image includes three headlines
The Washington Post 27 Feb 2019 article Opinion [should be Fact]: The U.S. is funding dangerous experiments it doesn’t want you to know about written by two of the hundreds of researchers, medical and public-health professionals, who oppose “experiments to enhance some of the world’s most lethal viruses by making them transmissible by air” linked to the Science.org exclusive posted a few weeks prior, on 8 Feb 2019 titled EXCLUSIVE: Controversial experiments that could make bird flu more risky poised to resume. The WaPo article also linked to an index of the Press Coverage for The Cambridge Working Group, where a Nature November 2015 article titled “Engineered bat virus stirs debate over risky research” is near the top.
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.